(A) Clonogenic survival assay for olaparib in HeLa control and HeLa_XRCC1_KO cells untreated or treated with olaparib. (B) Quantification of γH2AX levels by flow cytometry in HeLa control and HeLa_XRCC1_KO cells treated with olaparib. (C) Quantification of cell cycle progression by flow cytometry in in HeLa control and HeLa_XRCC1_KO cells treated with olaparib. (D) Quantification of apoptotic cells by annexin V flow cytometry in in HeLa control and HeLa_ XRCC1_KO cells treated with olaparib. (E) Quantification of γH2AX levels by flow cytometry in HeLa control and HeLa_BRCA2_KO cells treated with olaparib. (F) Representative photo micrographic images of 231 control, 231 (XRCC1_KO), 157 cells, HeLa control and HeLa_XRCC1_KD 3D-spheroids treated with AZD6738 (5 μM) or treated with AZD6738 (5 μM) plus olaparib (5 μM). (G) Quantification of spheroid size in 231control, 231 (XRCC1_KO) and 157 treated with AZD6738 (5 μM) or treated with AZD6738 (5 μM) plus olaparib (5 μM). (H) Quantification of viable, dead cells by flow cytometry in 231control, 231 (XRCC1_KO) and 157 treated with AZD6738 (5 μM) or treated with AZD6738 (5 μM) plus olaparib (5 μM). (I) Representative photo micrographic images of HeLa control and (XRCC1_KO) cells treated with AZD6738 (5 μM) or treated with AZD6738 (5 μM) plus olaparib (5 μM). (J) Quantification of spheroid size in 231control, 231 (XRCC1_KO) and 157 treated with AZD6738 (5 μM) or treated with AZD6738 (5 μM) plus olaparib (5 μM). (K) Quantification of viable, dead cells by flow cytometry in 231control, 231 (XRCC1_KO) and 157 treated with AZD6738 (5 μM) or treated with AZD6738 (5 μM) plus olaparib (5 μM).
*p⩽ 0.05; **p⩽ 0.01; ***p-value ⩽ 0.001.